One Pager as on September 30, 2025
![]() | Selection of focused sustainable businesses from across sectors |
![]() | Potential to generate higher risk adjusted returns in the long term |
![]() | Active management of portfolio with primary investments in mid-caps |
Sector | MMMCF* | Nifty Midcap 150 TRI |
Financial Services | 20.19% | 25.02% |
Healthcare | 15.04% | 8.69% |
Capital Goods | 12.83% | 14.34% |
Automobile And Auto Components | 12.50% | 7.93% |
Information Technology | 7.06% | 6.19% |
*Mahindra Manulife Mid Cap Fund
Data as on September 30, 2025
Security | % to Net Assets |
Glenmark Pharmaceuticals Limited | 3.11% |
Indian Bank | 2.99% |
UNO Minda Limited | 2.58% |
Blue Star Limited | 2.53% |
Tube Investments of India Limited | 2.39% |
Nippon Life India Asset Management Limited | 2.26% |
JK Cement Limited | 2.24% |
IDFC First Bank Limited | 2.22% |
Union Bank of India | 2.15% |
APL Apollo Tubes Limited | 2.13% |
Total | 24.60% |
Fresh Additions | Complete Exits |
Security | Security |
Piramal Finance Limited | Piramal Enterprises Limited |
- | Hindustan Petroleum Corporation Limited |
- | Voltas Limited |
- | REC Limited |
- | Escorts Kubota Limited |
- | - |
- | - |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant
portfolio changes during the month and should not be construed as recommendation to buy/sell/
hold. The fund manager may or may not choose to hold these companies/stocks, from time to
time. Investors are requested to consult their financial, tax and other advisors before taking any
investment decision(s). Data as on September 30, 2025
Turnover Ratio (Last 1 year) | 0.63 |
Standard Deviation | 15.31% |
Beta | 0.93 |
Sharpe Ratio# | 1.05 |
Jenson's Alpha | 0.0661 |
#Risk-free rate assumed to be 5.74% (MIBOR as on 30-09-25) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling
returns for last 3 years. Data as on September 30, 2025
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Jan-18.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth
Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period. Mr. Manish Lodha is managing this fund since December 21, 2020. Mr. Krishna Sanghavi is managing this fund since October 24, 2024. Ms. Kirti Dalvi is managing this fund since December 03, 2024
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-Jan-18.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of Growth Option
under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Krishna Sanghavi manages 6 schemes and Mr. Manish Lodha manages 10 schemes of Mahindra Manulife Mutual Fund. Ms. Kirti Dalvi manages 1 schemes of Mahindra Manulife Mutual Fund The performance data for the schemes which have not completed one year has not been provided.
Performance as on September 30, 2025
Note: The performance data of Mahindra Manulife Value Fund has not been provided as the scheme has not completed 1 year since inception. The said Scheme is managed by Mr. Krishna Sanghavi & Mr. Vishal Jajoo.
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in
equity and equity related securities
including derivatives of mid cap
companies.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.